Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis

被引：37

作者：

Aktas, O ^{[1
]}

Waiczies, S ^{[1
]}

Grieger, U ^{[1
]}

Wendling, U ^{[1
]}

Zschenderlein, R ^{[1
]}

Zipp, F ^{[1
]}

机构：

[1] Univ Hosp Charite, Div Neuroimmunol, Dept Neurol, D-10117 Berlin, Germany

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2001年 / 114卷 / 1-2期

关键词：

intravenous immunoglobulins; apoptosis; proliferation; multiple sclerosis; human;

D O I：

10.1016/S0165-5728(01)00243-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Polyspecific immunoglobulins (IVIg) have been shown to reduce disease activity in multiple sclerosis (MS). To investigate the mechanisms of action of IVIg, we studied the impact of IVIg on growth and death (apoptosis) of human (auto)antigen-specific T cells. We observed a substantial suppression of proliferation of specifically activated T cells, in absence of caspase activation or DNA fragmentation. Further, neither susceptibility of T cells to undergo CD95-mediated apoptosis nor expression of,apoptosis-blocking bcl-2 was modulated by Mg. We conclude that IVIg may inhibit the reactivity of antigen-specific T cells in MS through suppression of proliferation rather than modulation of apoptosis. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

页码：160 / 167

页数：8

共 37 条

[1] INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF EXPERIMENTAL T-CELL-MEDIATED AUTOIMMUNE-DISEASE - UP-REGULATION OF T-CELL PROLIFERATION AND DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA SECRETION [J].

ACHIRON, A ;

MARGALIT, R ;

HERSHKOVIZ, R ;

MARKOVITS, D ;

RESHEF, T ;

MELAMED, E ;

COHEN, IR ;

LIDER, O .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :600-605

[2] Intravenous immunoglobulin treatment in multiple sclerosis - Effect on relapses [J].

Achiron, A ;

Gabbay, U ;

Gilad, R ;

Hassin-Baer, S ;

Barak, Y ;

Gornish, M ;

Elizur, A ;

Goldhammer, Y ;

Sarova-Pinhas, I .

NEUROLOGY, 1998, 50 (02) :398-402

[3] Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro [J].

Alder, LBA ;

Morgan, LA ;

Spickett, GP .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 44 (06) :585-591

[4] SUPPRESSION OF CYTOKINE-DEPENDENT HUMAN T-CELL PROLIFERATION BY INTRAVENOUS IMMUNOGLOBULIN [J].

AMRAN, D ;

RENZ, H ;

LACK, G ;

BRADLEY, K ;

GELFAND, EW .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 73 (02) :180-186

[5] Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes macrophages [J].

Andersson, J ;

SkansenSaphir, U ;

Sparrelid, E ;

Andersson, U .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 :10-20

[6] SOLUBLE CD4, CD8, AND HLA MOLECULES IN COMMERCIAL IMMUNOGLOBULIN PREPARATIONS [J].

BLASCZYK, R ;

WESTHOFF, U ;

GROSSEWILDE, H .

LANCET, 1993, 341 (8848) :789-790

[7] Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases [J].

Dalakas, MC .

NEUROLOGY, 1998, 51 (06) :S2-S8

[8]

Eylar E H, 1974, Methods Enzymol, V32, P323

[9] Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis [J].

Fazekas, F ;

Deisenhammer, F ;

StrasserFuchs, S ;

Nahler, G ;

Mamoli, B .

LANCET, 1997, 349 (9052) :589-593

[10] SOLUBLE HLA CLASS-I AND CLASS-II CONCENTRATIONS IN COMMERCIAL IMMUNOGLOBULIN PREPARATIONS [J].

GROSSEWILDE, H ;

BLASCZYK, R ;

WESTHOFF, U .

TISSUE ANTIGENS, 1992, 39 (02) :74-77

← 1 2 3 4 →